Pharma Pulse: Global AI Alignment, the TrumpRx Pivot, and Nano-Delivery GLP-1s

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.

• First, the FDA and EMA have released a joint framework for AI use in drug development. Centered on 10 guiding principles, this alignment aims to harmonize how developers document and validate AI models. The goal? To slash development timelines while ensuring "human-centric" safety standards across both the US and EU.
• In the US, a new report shows a growing divide in pricing strategy. While list prices rose by median of 4% in 2026, drug companies have hiked up the price of 872 different name brand medications. Amongst the companies raising list prices are 16 of the largest pharma groups that have now signed direct agreements with the Trump administration to join TrumpRx.
• Lastly, BoomRx has expanded access to oral semaglutide and tirzepatide using advanced nanoemulsion delivery. By converting doses into ultra-small droplets, the tech significantly boosts bioavailability, offering a consistent, needle-free alternative for weight management.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.